It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 13:23:24 Source:healthViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
You may also like
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
- Reims and Rennes drop points in the French league chase for a European place
- Preserving world
- Full Text: Remarks by Chinese President Xi Jinping at China
- Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gang
- State Council stresses work on flood relief, rebuilding
- Xi extends congratulations to National University of Defense Technology on 70th anniversary
- Xi replies to letter from Chinese paratroopers
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East